Peter L. Stern

14.5k total citations · 1 hit paper
210 papers, 10.7k citations indexed

About

Peter L. Stern is a scholar working on Immunology, Epidemiology and Molecular Biology. According to data from OpenAlex, Peter L. Stern has authored 210 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Immunology, 65 papers in Epidemiology and 63 papers in Molecular Biology. Recurrent topics in Peter L. Stern's work include Immunotherapy and Immune Responses (81 papers), Cervical Cancer and HPV Research (58 papers) and Immune Cell Function and Interaction (28 papers). Peter L. Stern is often cited by papers focused on Immunotherapy and Immune Responses (81 papers), Cervical Cancer and HPV Research (58 papers) and Immune Cell Function and Interaction (28 papers). Peter L. Stern collaborates with scholars based in United Kingdom, United States and Netherlands. Peter L. Stern's co-authors include Teresa Cabrera, Francisco Ruiz‐Cabello, Federico Garrido, Richard B.S. Roden, Robert E. Hawkins, Christopher M. Ward, Henry C Kitchener, Eyad Elkord, Susan Glew and Margaret Duggan‐Keen and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Peter L. Stern

209 papers receiving 10.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

1997 627 citations Federico Garrido, Francisco Ruiz‐Cabello et al. Immunology Today profile →

Peers

Countries citing papers authored by Peter L. Stern

Since Specialization

Citations

This map shows the geographic impact of Peter L. Stern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter L. Stern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter L. Stern more than expected).

Fields of papers citing papers by Peter L. Stern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter L. Stern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter L. Stern. The network helps show where Peter L. Stern may publish in the future.

Co-authorship network of co-authors of Peter L. Stern

This figure shows the co-authorship network connecting the top 25 collaborators of Peter L. Stern. A scholar is included among the top collaborators of Peter L. Stern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter L. Stern. Peter L. Stern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen 2019 ·SHILAP Revista de lepidopterología ·Richard Harrop, Eric O’Neill, Peter L. Stern	15
2	STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs 2016 ·Cancer Research ·Barbara Walch‐Rückheim, (unknown), (unknown), Claudia Wickenhauser, Lars Christian Horn, Lars Tharun, Reinhard Büttner, Peter Mallmann, Peter L. Stern, Yoo-Jin Kim, Rainer M. Bohle, Christian Rübe, (unknown), Ingolf Juhasz‐Böss, Erich‐Franz Solomayer, Sigrun Smola	43
3	5T4 oncofoetal antigen: an attractive target for immune intervention in cancer 2016 ·Cancer Immunology Immunotherapy ·Peter L. Stern, Richard Harrop	55
4	Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy 2011 ·Cancer Immunology Immunotherapy ·Fernanda Castro, (unknown), (unknown), Hui‐Rong Jiang, Jan W. Drijfhout, Sumia Ali, Andrzej Rutkowski, (unknown), David E. Gilham, Peter L. Stern	7
5	CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells 2010 ·PLoS ONE ·Thomas D. Southgate, (unknown), Fernanda Castro, Andrzej Rutkowski, (unknown), Georgi K. Marinov, (unknown), David Shaw, Christopher M. Ward, Crispin Miller, Peter L. Stern	40
6	Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors 2006 ·The Journal of Immunology ·Hui‐Rong Jiang, David E. Gilham, (unknown), Н. А. Кириллова, Robert E. Hawkins, Peter L. Stern	24
7	A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei 2006 ·British Journal of Cancer ·(unknown), N Pranesh, Mark Saunders, Malcolm Wilson, Sarah O’Dwyer, Peter L. Stern, Andrew G. Renehan	32
8	Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia 2005 ·Developmental Dynamics ·(unknown), Christopher M. Ward, (unknown), Sumia Ali, Peter L. Stern	34
9	Use of adenoviruses encoding CD40L or IL‐2 against B cell lymphoma 2004 ·International Journal of Cancer ·(unknown), Tapan Bhattacharyya, Anne Armstrong, Cheng Qian, Robert E. Hawkins, Peter L. Stern, Said Dermime	16
10	Significant variations in differentiation properties between independent mouse ES cell lines cultured under defined conditions 2003 ·Experimental Cell Research ·Christopher M. Ward, (unknown), Peter L. Stern	43
11	Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope 2002 ·The Journal of Immunology ·Anne Armstrong, Said Dermime, (unknown), Tapan Bhattacharyya, (unknown), (unknown), Peter L. Stern, Robert E. Hawkins	42
12	Cancer vaccines and immunotherapy 2002 ·British Medical Bulletin ·Said Dermime, Anne Armstrong, Robert E. Hawkins, Peter L. Stern	51
13	Does HLA type predispose some individuals to cancer? 1999 ·Molecular Medicine Today ·Ann-Margaret Little, Peter L. Stern, (unknown)	20
14	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours breakdown → 1997 ·Immunology Today ·Federico Garrido, Francisco Ruiz‐Cabello, Teresa Cabrera, Juan J. Pérez‐Villar, Miguel López‐Botet, (unknown), Peter L. Stern	627
15	The clinical significance of p53 accumulation in gastric carcinoma 1996 ·Cancer ·Teresa Starzyñska, Maciej M. Markiewski, W Domagała, K Marlicz, (unknown), Stephen A. Roberts, Peter L. Stern	4
16	The clinical significance of p53 accumulation in gastric carcinoma 1996 ·Cancer ·Teresa Starzyñska, Maciej M. Markiewski, W Domagała, K Marlicz, (unknown), Stephen K. Roberts, Peter L. Stern	39
17	Human papillomaviruses and cervical cancer : biology and immunology 1994 ·Oxford University Press eBooks ·Peter L. Stern, Margaret Stanley	14
18	Identification of a naturally processed HLA A0201‐restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein 1994 ·European Journal of Immunology ·Jennifer S. Bartholomew, Simon Stacey, Brian Coles, Deborah J. Burt, John R. Arrand, Peter L. Stern	33
19	SINGLE-CHANNEL KINETICS OF RECOMBINANT NMDA RECEPTORS 1993 ·UCL Discovery (University College London) ·Peter L. Stern, (unknown), Ralf Schoepfer, David Colquhoun	3
20	Murine Lymphocyte and Embryonal Carcinoma Cell Surface Antigens Recognised by Rabbit Anti-Murine Embryonal Carcinoma Serum 1986 ·Pathobiology ·Peter L. Stern, (unknown), (unknown), Stephen Thompson	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact